![](https://i.imgur.com/CLvY2jA.png")
07-01-2022, 04:03 PM
Given that even after three or four doses mRNA vaccines were not effective in stopping COVID-19 variants like Omicron, it was necessary to “balance the portfolio” by focusing on quantity of vaccines rather than the newest technology, Dr. Hotez observed.
Traditional vaccines such as a virion (entire virus particle) and subunit ones (pathogen fragment) contain inactivated parts of the virus that enter the body as antigens and trigger an immune response.
Newer technologies such as the mRNA or DNA vaccines contain modified genes that use the body’s cells to make the immune-triggering antigen.
The latter approach is also believed to be quicker and more customisable to making vaccines for several pathogens in the future. However, none of the commercially available COVID-19 vaccines are yet customised to the Delta or Omicron variants.
https://www.thehindu.com/sci-tech/health...epage=true
Traditional vaccines such as a virion (entire virus particle) and subunit ones (pathogen fragment) contain inactivated parts of the virus that enter the body as antigens and trigger an immune response.
Newer technologies such as the mRNA or DNA vaccines contain modified genes that use the body’s cells to make the immune-triggering antigen.
The latter approach is also believed to be quicker and more customisable to making vaccines for several pathogens in the future. However, none of the commercially available COVID-19 vaccines are yet customised to the Delta or Omicron variants.
https://www.thehindu.com/sci-tech/health...epage=true
